Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The aims of this vaccine trial are: (1) to measure humoral and selected cellular immune responses to repeated influenza vaccination with Flublok, including these responses' associations with age, birth year, and prior vaccination history; (2) to identify the characteristics of study participants who are vaccinated but still become infected with influenza virus ("vaccine failures") and participants who have poor immune responses to vaccination; and (3) to predict how influenza vaccinations and infections shape immunity.
Description: The proportion of participants who achieve a target rise in antibody titre against each of the vaccine strains at 30 days (the targeted rise in antibody titre is defined as the proportion of participants with a four-fold or greater rise in titer, i.e. either a pre-vaccination hemagglutination inhibition titer <10 and a post-vaccination hemagglutination inhibition titre ≥20, or a pre- vaccination hemagglutination inhibition titer ≥10 and at least a four-fold rise in post-vaccination hemagglutination inhibition antibody titer)
Measure: Immune response to vaccination (4-fold rise in titer at day 30) Time: 30 days after vaccinationDescription: The geometric mean titer (GMT) ratios between the vaccine group and the comparator group (placebo) against each of the vaccine strains at 30 days and 182 days
Measure: Immune response to vaccination (GMT ratio at day 30 and 182) Time: 30 days and 182 days after vaccinationDescription: The proportion of participants who achieve an HAI titer ≥40 after each vaccination (or neutralization assay for H3N2 and any other non-hemagglutinating strains).
Measure: Immune response to vaccination (antibody titer >=40 at day 30 and 182) Time: 30 days and 182 days after vaccinationDescription: The vaccine-induced influenza-specific CD4+ and CD8+ T cell responses 7 and 30 days post-vaccination, including cytokine production evaluated by Intracellular Cytokine Staining (ICS) assay. Responses for these and other relevant biomarkers are compared to the corresponding pre-vaccination values for each participant.
Measure: Immune response to vaccination (cell-mediated immunity) Time: 7 days and 30 days after vaccinationDescription: The fine-grained specificity and phenotypes of antibodies and influenza-positive B and T cell populations before and after vaccination and natural infection.
Measure: Immune response to vaccination (antibody specificity) Time: 30 days and 182 days after vaccinationDescription: The rate of adverse events within 30 days after receipt of vaccination or placebo
Measure: Incidence of reactions after vaccination [Safety] Time: 30 days after vaccinationDescription: The rate of polymerase chain reaction (PCR)-confirmed influenza virus infection.
Measure: Incidence of laboratory-confirmed influenza after vaccination (vaccine failure) Time: One year after vaccinationDescription: The occurrence of other respiratory infections, including COVID-19 infections, in participants, determined by PCR or serology
Measure: Incidence of other respiratory infections Time: One year after vaccinationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports